NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Publication
, Journal Article
Wierda, WG; Zelenetz, AD; Gordon, LI; Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Byrd, JC; Caimi, P; Fayad, LE; Fisher, RI; Kim, YH ...
Published in: J Natl Compr Canc Netw
March 2017
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2017
Volume
15
Issue
3
Start / End Page
293 / 311
Location
United States
Related Subject Headings
- Treatment Outcome
- Retreatment
- Recurrence
- Oncology & Carcinogenesis
- Neoplasm Staging
- Molecular Targeted Therapy
- Leukemia, Lymphocytic, Chronic, B-Cell
- Humans
- Drug Resistance, Neoplasm
- Comorbidity
Citation
APA
Chicago
ICMJE
MLA
NLM
Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw, 15(3), 293–311. https://doi.org/10.6004/jnccn.2017.0030
Wierda, William G., Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, Nancy Bartlett, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.” J Natl Compr Canc Netw 15, no. 3 (March 2017): 293–311. https://doi.org/10.6004/jnccn.2017.0030.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017 Mar;15(3):293–311.
Wierda, William G., et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.” J Natl Compr Canc Netw, vol. 15, no. 3, Mar. 2017, pp. 293–311. Pubmed, doi:10.6004/jnccn.2017.0030.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017 Mar;15(3):293–311.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2017
Volume
15
Issue
3
Start / End Page
293 / 311
Location
United States
Related Subject Headings
- Treatment Outcome
- Retreatment
- Recurrence
- Oncology & Carcinogenesis
- Neoplasm Staging
- Molecular Targeted Therapy
- Leukemia, Lymphocytic, Chronic, B-Cell
- Humans
- Drug Resistance, Neoplasm
- Comorbidity